Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients

J Infect. 2005 Apr;50(3):221-8. doi: 10.1016/j.jinf.2004.04.003.

Abstract

Objective: To determine the disease progression of HIV-HCV co-infected hemophiliacs in a large cohort of patients (n = 288) cared for at a single medical institution.

Patients and methods: Annual mortality rates for AIDS- and liver-related death were calculated and Kaplan-Meier survival plots were drawn to determine the progression to AIDS and death.

Results: Between January 1985 and December 2002, 179 (62.2%) and 195 (67.7%) of these patients had developed AIDS or died, respectively. Overall, AIDS accounted for 128 deaths, which almost entirely (93.7%) occurred prior to the introduction of highly active antiretroviral therapy (HAART) at the end of 1995. A total of 29 patients died of liver failure, most of them (69%) during the years 1991-1996. Since 1997, only five cases of fatal liver failure were reported. Non-HIV-HCV related reasons were responsible for 38 deaths and occurred predominantly (47%) in the years 1997-2002. Starting November 1995, 72 patients were treated with HAART. However, by December 2002, only 52.5% and 83% of all HAART-treated patients had a stable viremia (<400 copies/ml) and a sufficient CD4(+) T-cell count (>200/microl), respectively.

Conclusion: These data indicate that liver-related mortality peaked in the years 1991-1996, but subsequently tended to decline. Moreover, despite widespread treatment of patients with HAART, a significant proportion of individuals had an unsatisfactory immunological and virological status at the end of 2002.

MeSH terms

  • Acquired Immunodeficiency Syndrome / epidemiology
  • Adolescent
  • Adult
  • Anti-HIV Agents
  • Antiretroviral Therapy, Highly Active
  • Child
  • Child, Preschool
  • Cohort Studies
  • Disease Progression
  • HIV Infections / complications*
  • HIV Infections / mortality
  • Hemophilia A / complications*
  • Hemophilia B / complications*
  • Hepatitis C / complications*
  • Hepatitis C / mortality
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Time Factors

Substances

  • Anti-HIV Agents